Abstract
on AIs should have baseline dexa scan within 3 months of commencement. Calcium tablets or bisphosphonates should be given if osteopaenia or osteoporosis is identified. We aimed to compare our current practice with NICE guidelines (CG80). Methods: Patients were prospectively identified from breast follow up clinics during a 4 month period (August 2014eNovember 2014). Demographics, adjuvant therapy and bone health management plans were recorded and analysed. Results: 22 patients were identified. Median age was 66, range [55e92]. 18% were on neoadjuvant hormonal therapy. The majority of patients (86%) were on letrozole whereas 7% of patients were on exemestane and 7% on anastrozole. A clear bone health management plan was achieved in 30% of patients. 45.5% (10/22) of patients had a baseline DEXA scan, 40% (4/10) of those within timeframe. 70% (7/10) of patients had normal baseline DEXA scan and all have received lifestyle advice. Osteoporosis and osteopaenia was reported in 20% (2/10) and 10% (1/ 10) of patients respectively. All patients with osteoporosis were on bisphosphonates. In patients with osteopaenia there was no evidence of information for receiving additional calcium medications. Conclusions: Baseline bone health is poorly characterised in this series. It is crucial to assess bone density and a clear system needs to be developed in order to optimise bone health.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call